Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Other Accumulated Expenses: 2013-2024

Historic Other Accumulated Expenses for Ocular Therapeutix (OCUL) over the last 12 years, with Dec 2024 value amounting to $2.1 million.

  • Ocular Therapeutix's Other Accumulated Expenses rose 6.42% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 6.42%. This contributed to the annual value of $2.1 million for FY2024, which is 34.75% up from last year.
  • According to the latest figures from FY2024, Ocular Therapeutix's Other Accumulated Expenses is $2.1 million, which was up 34.75% from $1.5 million recorded in FY2023.
  • Ocular Therapeutix's Other Accumulated Expenses' 5-year high stood at $2.1 million during FY2024, with a 5-year trough of $941,000 in FY2020.
  • For the 3-year period, Ocular Therapeutix's Other Accumulated Expenses averaged around $1.6 million, with its median value being $1.5 million (2023).
  • Data for Ocular Therapeutix's Other Accumulated Expenses shows a peak YoY spiked of 68.64% (in 2020) over the last 5 years.
  • Over the past 5 years, Ocular Therapeutix's Other Accumulated Expenses (Yearly) stood at $941,000 in 2020, then climbed by 17.43% to $1.1 million in 2021, then increased by 11.13% to $1.2 million in 2022, then rose by 24.19% to $1.5 million in 2023, then skyrocketed by 34.75% to $2.1 million in 2024.